Crinetics Pharmaceuticals (CRNX) Change in Acquisitions & Divestments (2019 - 2026)

Crinetics Pharmaceuticals has reported Change in Acquisitions & Divestments for 8 years, with the latest figure at $302.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 1.17% year-over-year to $302.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 51.17% YoY), and the FY2025 full-year result was $1.2 billion, up 105.64% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $302.9 million, up from $271.2 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $382.4 million in Q3 2025, with the low at $11.7 million in Q1 2022.
• Average Change in Acquisitions & Divestments over 5 years is $150.4 million, with a median of $101.4 million recorded in 2024.
• Peak annual rise in Change in Acquisitions & Divestments reached 28870.49% in 2022, while the deepest fall reached 66.66% in 2022.
• Tracing CRNX's Change in Acquisitions & Divestments over 5 years: stood at $70.7 million in 2022, then climbed by 22.62% to $86.7 million in 2023, then jumped by 112.24% to $184.0 million in 2024, then jumped by 47.42% to $271.2 million in 2025, then climbed by 11.68% to $302.9 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $302.9 million (Q1 2026), $271.2 million (Q4 2025), and $382.4 million (Q3 2025), per Business Quant data.

Peer Comparison